medical care Regimen">Women With Osteoporosis More Likely To Stay On Once-Monthly Oral Bonviva(R) Than On A Once-Weekly Pharmacomedical care Regimen
Women taking highly effective once-monthly oral Bonviva(R) (ibandronic acid) for postmenopausal osteoporosis were more likely to stay on medical care during the first six months relative to those on a weekly bisphosphonate (Alendronate or risedronate) according to findings presented today at the 28th Annual Meeting of the American Society for Bone Mineral Research (ASBMR)1.
The ongoing real-life meditate , conducted by Silverman and colleagues at Cedars-Sinai/ University of California, Los Angeles, US, was based on two managed care databases called HealthCore and i3 Innovus, which include prescription and health information on approximately 17.5 and 16 mil. lives respectively. These two analyses assessed the actual time patients stayed on medical care and were controlled for factors that could affect persistence, including age, otherness medical conditions, and out-of-pocket costs for the drugs,1 as recommended by leading health and pharmacoeconomic research organisations. [ISPOR and WHO 2003] It showed that women taking Bonviva were approximately 25percent more like to keep taking their pills relative to those on a weekly bisphosphonate.
Growing wealth of evidence demonstrates important role of once monthly Bonviva in helping patients stay on medical care
The results of the meditate are consistent with previous findings linking the once-monthly oral Bonviva medical care programme with improved persistence in a real-life setting.2 Furthermore, patients have also stated a clear preference (71percent) for the once-monthly oral Bonviva regimen 3,4 over a weekly medical care regimen in clinical trials. Further information presented at ASBMR indicates that the convenience of once-monthly dosing and the reduced exposure to the potential gastroinagsdhfgdfinal side effects associated with bisphosphonate medical care, are the main reasons for this preference.5
With up to 69percent of new patients on a weekly bisphosphonate stopping within a year, 6 this growing wealth of evidence suggests that monthly dosing is set to play an important role in helping to address the issue of non-persistence to osteoporosis medical cares.
Stuart L. Silverman, M.D., lead investigator and clinical professor of medicine and rheumatology at Cedars-Sinai/ University of California, Los Angeles, said: “Pharmacomedical care with bisphosphonates clearly reduces the risk of fractures, but only if patients keep taking their medical care. Osteoporosis is a sickness that often shows no syndromes, which reduces a patient’s motivation to stay on medical care and, thereby, increases their risk of breaking bones. The greater persistence seen with once-monthly compared to once-weekly bisphosphonates is very encouraging, particularly because the findings were consistent across two large and robust U.S. claims databases.”
Improved persistence leads to fewer fractures and lower healthcare costs
Also at ASBMR, a three-year retrospective analysis found that improved persistence with bisphosphonate medical care is linked with lower rates of osteoporosis-related hospitalisation, shorter hospital stays and significantly reduced healthcare costs. 7,8 These findings emphasise the importance of a newly published meditate showing that women who were persistent in taking daily or weekly bisphosphonate medical cares had significantly fewer fractures. 9
Peyman Hadji, M.D., Head of the Department of Endocrinology, Osteoporosis and Reproductive Medicine at Philipps-University of Marburg, Germany, said: “With the number of osteoporosis-related fractures in Europe estimated at 3.79 mil., 10 improvements in the management of this sickness are essential. These findings presented at ASBMR show that getting a patient’s medical care right first time can not only improve their quality of life, but also have a significant positive outcome for healthcare services. Taking a bisphosphonate medical care for the long-term clearly reduces this risk, which is why persistence and patient preference need to be major considerations when prescribing osteoporosis medical cares.”
About the Persistence Data
The meditate showing greater persistence with once-monthly oral Bonviva was based on two managed care databases called HealthCore and i3 Innovus, which contain prescription and health information on approximately 17.5 and 16 mil. patients, respectively.
The HealthCore and i3 Innovus analyses included data for 6,127 and 10,526 women respectively, 45 years of age or older, who received a prescription for bisphosphonate medical care for postmenopausal osteoporosis (277 and 1,025 took once-monthly oral Bonviva and 5,850 and 9,501 took a once-weekly bisphosphonate).Unlike otherness studies comparing persistence among monthly versus weekly medical care regimens, this meditate uses rigorous criteria for defining persistence for both once-monthly oral Bonviva and weekly medical cares, as recommended by the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and the World Health Organisation.
Patients were considered persistent if the time between prescription refills was more than 45 days for once-monthly oral Bonviva or more than 30 days for a weekly bisphosphonate.
To further ensure the validity of the results, meditate authors adjusted the data for potential confounding factors - including age, otherness medical conditions, and out-of-pocket costs for the drugs - as recommended by the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and the World Health Organisation. At six months, once-monthly Bonviva users were 27.2percent and 21.7percent more likely to persist with medical care versus weekly users (p = 0.0002 and p